Key Highlights

  • Loss per share was USD 0.17 against an estimate of a USD 0.16 loss.
  • Net loss was USD 42.99 million, against USD 29.56 million a year earlier.
  • Total operating expenses were USD 43.54 million, against USD 30.26 million.
  • Cash was USD 29.8 million and short-term investments were USD 99.8 million.

Savara (NASDAQ:SVRA) reported a third quarter 2026 loss per share of USD 0.17, against an estimate of a USD 0.16 loss and a USD 0.14 loss in the third quarter of 2025. Net loss was USD 42.99 million, compared with USD 29.56 million.

The loss from operations was USD 43.54 million, compared with USD 30.26 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses

Research and development expenses were USD 24.95 million, compared with USD 20.59 million. General and administrative expenses were USD 18.54 million, compared with USD 9.63 million. Total operating expenses were USD 43.54 million, against USD 30.26 million.

The filing reports share-based compensation within Research and Development expenses of USD 2.26 million, compared with USD 1.11 million, and within general and administrative expenses of USD 5.57 million, compared with USD 2.32 million.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 120.50 million, compared with USD 86.60 million, and the loss per share was USD 0.47, against USD 0.40. Total operating expenses were USD 123.50 million, against USD 90.13 million.

Research and development expenses for the nine months were USD 70.29 million, against USD 60.50 million, and general and administrative expenses were USD 53.10 million, against USD 29.53 million. Share-based compensation within research and development expenses for the nine months was USD 7.88 million, against USD 2.40 million, and within general and administrative expenses was USD 18.44 million, against USD 6.67 million.

Program Status and Liquidity

The filing describes the company's sole program, molgramostim inhalation solution, known as MOLBREEVI, as an investigational inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor, that is in Phase 3 development and under regulatory review in the United States, the European Union and the United Kingdom.

As of September 30, 2026, the company had an accumulated Deficit of approximately USD 728.6 million, cash and cash equivalents of USD 29.8 million and short-term investments of USD 99.8 million. Based on its current operating plan, the company believes its existing cash and cash equivalents and short-term investments are sufficient to fund its operations for at least the next twelve months from the date the financial statements are issued.

The filing also states that, although the company has sufficient Capital to fund many of its planned activities, it may need to continue to raise additional capital to further fund development of, and seek regulatory approvals for, its product candidate and begin to commercialize any approved product.

Savara Q3 2026 Earnings: Key Takeaways

Savara reported a third quarter 2026 loss per share of USD 0.17 and a net loss of USD 42.99 million. Research and development expenses were USD 24.95 million, cash and cash equivalents were USD 29.8 million, and short-term investments were USD 99.8 million.